Myogen, Novartis expand cardiovascular deal

MYOG and Novartis (NVS; SWX:NOVN) expanded their 2003 cardiovascular deal to include MYOG's HDAC inhibitor research program. MYOG will now receive an additional three years of research funding and sig...